These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 1678683

  • 1. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.
    Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK.
    Cancer Res; 1991 Sep 01; 51(17):4575-80. PubMed ID: 1678683
    [Abstract] [Full Text] [Related]

  • 2. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line.
    Langton-Webster BC, Xuan JA, Brink JR, Salomon DS.
    Cell Growth Differ; 1994 Dec 01; 5(12):1367-72. PubMed ID: 7696185
    [Abstract] [Full Text] [Related]

  • 3. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.
    Cancer Res; 1994 Jul 15; 54(14):3758-65. PubMed ID: 7913407
    [Abstract] [Full Text] [Related]

  • 4. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC.
    Clin Cancer Res; 2000 Aug 15; 6(8):3334-41. PubMed ID: 10955821
    [Abstract] [Full Text] [Related]

  • 5. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 6. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I.
    Cancer Res; 1993 Jan 01; 53(1):94-100. PubMed ID: 8093231
    [Abstract] [Full Text] [Related]

  • 7. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
    Shawver LK, Mann E, Elliger SS, Dugger TC, Arteaga CL.
    Cancer Res; 1994 Mar 01; 54(5):1367-73. PubMed ID: 7907001
    [Abstract] [Full Text] [Related]

  • 8. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
    Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE.
    Cancer Res; 1991 May 15; 51(10):2593-8. PubMed ID: 1673637
    [Abstract] [Full Text] [Related]

  • 9. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
    Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O.
    Cancer Res; 1995 Feb 01; 55(3):590-6. PubMed ID: 7834629
    [Abstract] [Full Text] [Related]

  • 10. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
    Uslu R, Jewett A, Bonavida B.
    Gynecol Oncol; 1996 Aug 01; 62(2):282-91. PubMed ID: 8751562
    [Abstract] [Full Text] [Related]

  • 11. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y, Yoshida O, Bonavida B.
    J Urol; 1998 Aug 01; 160(2):561-70. PubMed ID: 9679929
    [Abstract] [Full Text] [Related]

  • 12. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
    Qamar L, Davis R, Anwar A, Behbakht K.
    Gynecol Oncol; 2008 Sep 01; 110(3):425-31. PubMed ID: 18619662
    [Abstract] [Full Text] [Related]

  • 13. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D, Wolf JK, Scanlon M, Price JE, Hung MC.
    Cancer Res; 1993 Feb 15; 53(4):891-8. PubMed ID: 8094034
    [Abstract] [Full Text] [Related]

  • 14. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
    Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ.
    Oncogene; 1994 Jul 15; 9(7):1829-38. PubMed ID: 7911565
    [Abstract] [Full Text] [Related]

  • 15. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II).
    Kikuchi Y, Hirata J, Hisano A, Tode T, Kita T, Nagata I.
    Gynecol Oncol; 1995 Jul 15; 58(1):11-5. PubMed ID: 7789875
    [Abstract] [Full Text] [Related]

  • 16. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
    Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX.
    Cancer Res; 1996 Mar 15; 56(6):1457-65. PubMed ID: 8640840
    [Abstract] [Full Text] [Related]

  • 17. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway.
    Yen L, Nie ZR, You XL, Richard S, Langton-Webster BC, Alaoui-Jamali MA.
    Oncogene; 1997 Apr 17; 14(15):1827-35. PubMed ID: 9150389
    [Abstract] [Full Text] [Related]

  • 18. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.
    Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y, Bast RC.
    Cancer Res; 1991 Oct 01; 51(19):5361-9. PubMed ID: 1680547
    [Abstract] [Full Text] [Related]

  • 19. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells.
    Futagami M, Sato S, Sakamoto T, Yokoyama Y, Saito Y.
    Gynecol Oncol; 2001 Sep 01; 82(3):544-9. PubMed ID: 11520153
    [Abstract] [Full Text] [Related]

  • 20. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B.
    Clin Cancer Res; 1999 Apr 01; 5(4):865-74. PubMed ID: 10213223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.